Cargando…
Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
The rapid rise in the prevalence of type 2 diabetes mellitus (T2DM) poses a huge healthcare burden across the world. Although there are several antihyperglycaemic agents (AHAs) available including addition of new drug classes to the treatment algorithm, more than 50% of patients with T2DM do not ach...
Autores principales: | Fujiwara, Yuki, Eguchi, Shunsuke, Murayama, Hiroki, Takahashi, Yuri, Toda, Mitsutoshi, Imai, Kota, Tsuda, Kinsuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613229/ https://www.ncbi.nlm.nih.gov/pubmed/31294084 http://dx.doi.org/10.1002/edm2.68 |
Ejemplares similares
-
GLP-1 physiology informs the pharmacotherapy of obesity
por: Drucker, Daniel J.
Publicado: (2021) -
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
por: Liberini, Claudia G., et al.
Publicado: (2019) -
Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey
por: Murayama, Hiroki, et al.
Publicado: (2018) -
Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians’ Perspective in a Real-World Setting, Insight from a Web Survey
por: Imai, Kota, et al.
Publicado: (2018) -
Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes
por: Wong, Gunther, et al.
Publicado: (2023)